Successful use of the Impella Recover LP 5.0 device for circulatory support during off-pump coronary artery bypass grafting  by Pepino, Paolo et al.
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INTRODUCTION:  Surgical  coronary  revascularization  is  being  performed  with  ever  increasing  frequency  in
patients  at  high  surgical  risk. Off-pump  coronary  artery  bypass  grafting  (OPCABG)  is particularly  appealing
in such  subjects,  but may  limit  the options  for concomitant  mechanical  circulatory  support.
PRESENTATION  OF  CASE:  We  hereby  report  an  original  case  of  mechanical  circulatory  support  with  the
Impella  Recover  LP  5.0  device  during  OPCABG  in  a 61-year-old  gentleman  with  multiple  comorbidities
and  severe  left ventricular  systolic  dysfunction.  Speciﬁcally,  the  soft tipped  device  did not impede  surgical
manipulation  of  the heart  during  the  surgical  procedure,  providing  uninterrupted  circulatory  support  tompella
echanical circulatory support
the  patient.
DISCUSSION:  This  clinical  vignette  supports  the feasibility,  safety  and  efﬁcacy  of the  Impella  Recover  LP
5.0  device  in  patients  undergoing  OPCABG.
CONCLUSION:  Pending  further  studies,  use  of the  Impella  Recover  LP  5.0  device  can  be  envisioned  safely
for  OPCABG.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
 the Caccess  article  under
. Introduction
Given the increased life expectancy of patients with coronary
rtery disease (CAD) and the aging population, cardiac surgery is
eing increasingly performed in older and sicker patients. Accord-
ngly, means to reduce the risk of short-term complications are
eing actively sought. Off-pump coronary artery bypass grafting
OPCABG) is a typical paradigm, as it may  reduce peri-procedural
dverse events (e.g. stroke).
However, the fact that OPCABG is favored in high-risk patients
oses a clinical conundrum, as often the very same patients who
re ideal candidates for OPCABG may  not tolerate cardiac surgery
ithout additional mechanical circulatory support. Among theeveral mechanical circulatory support strategies currently avail-
ble, the most effective ones are typically also more invasive than
he least effective ones. In this scenario, the recently developed
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Impella device (Abiomed, Danvers, MA,  USA) might represent a
favorable compromise between effective circulatory support and
limited invasiveness.1 However, the cardiac manipulations typi-
cally required during off-pump CABG have to date considered a
major contraindication to the use of the Impella device in such
operative setting, as they may  conceivably lead to device malfunc-
tion, damage, valve dysfunction, or thrombosis.2,3 Accordingly, only
minimal experience has been accrued so far on this indication for
the Impella device.4,5
We report a patient who  successfully and safely underwent
OPCABG with concomitant mechanical circulatory support accom-
plished by the Impella device.
2. Presentation of case
A 61-year-old gentleman was admitted to our institution for
ischemic cardiomyopathy. Because of long-standing dyspnea and
recent onset of angina for mild efforts, the patient had undergone
echocardiography which showed severely depressed left ventri-
cular ejection fraction (LVEF, 25%) and mild mitral regurgitation.
Subsequent coronary angiography disclosed three-vessel CAD. Sev-
eral comorbidities were present, including non-insulin-dependent
ssociates Ltd. This is an open access article under the CC BY-NC-SA license
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iabetes mellitus, chronic obstructive pulmonary disease, renal
ailure, and hypothyroidism. Accordingly, a 10.5% in-hospital mor-
ality risk was computed with the EuroSCORE II model.
After heart team consensus, OPCABG was chosen as revascu-
arization strategy. In addition, we perused several of the typical
ossible alternatives for ancillary mechanical circulatory support,
s the patient had required prolonged levosimendan therapy after
oronary angiography and was not likely to face a successful oper-
tive outcome without circulatory support. While the intra-aortic
alloon pump (IABP) is most commonly used for mechanical sup-
ort in high-risk patients undergoing cardiac surgery, it is less likely
o improve tissue perfusion in comparison to the Impella, which is
ell known for its superior mechanical support,6 especially when
he Impella LP 5.0 version is used. Accordingly, we ﬁnally chose
he Impella device. Despite the potential untoward effects on the
evice itself related to the manipulations required during off-pump
urgery, we felt indeed that the soft-tipped device could provide
ontinuous and interrupted support to the patient while not imped-
ng the surgical procedure.
After preliminary lower limb duplex ultrasound to exclude
eripheral artery disease, an Impella Recover LP 5.0 device was
eployed via surgical cutdown of the right femoral artery and
uccessfully deployed in the left ventricle, with anticoagulation
btained with weight adjusted doses of unfractioned heparin
aiming to an activated clotting time between 200 and 150 s).
ubsequently, OPCABG was performed preparing a left internal
ammary artery (LIMA) graft to the left anterior descending, and a
equential radial artery jump graft from the LIMA graft to the ﬁrst
iagonal branch and the ramus intermedius, using the Octopus sta-
ilizer and the Urchin retractor (Medtronic, Minneapolis, MN,  USA).
o bypass was prepared for the obtuse marginal branches and the
istal right coronary artery as these vessels were too diseased and
hus unsuitable for grafting. Ongoing peri-procedural monitoring
as achieved with transesophageal echocardiography. The proce-
ure could be performed safely and effectively, without any undue
nterference from the Impella device, which was subsequently left
n place for an additional time of 24 h.
The patient fared well and was discharged home 9 days after
dmission. Predischarge transthoracic echocardiography showed
 mild improvement in LVEF (30%). One month later the patient
as asymptomatic for dyspnea or angina, with satisfactory
ffort tolerance, and control echocardiography showed additional
mprovement in LVEF (40%).
. Discussion
Several options are available for cardiac surgeons wishing to
inimize the risk of peri-operative complications in patients
ndergoing cardiothoracic surgery. There is however a typical
rade-off between the degree of invasiveness and the ability of
ny given approach or strategy to provide durable and effective
esults. In other words, minimally invasive surgical options typi-
ally offer slightly lower chances of long-term success than more
nvasive approaches.
Another important limitation of minimally invasive cardiac sur-
ical procedures is that they limit the options for several ancillary
ools and devices. OPCABG represents a paradigmatic example of
inimally invasive cardiac surgery. It offers good long-term results
nd reduces the risk of short-term complications. Yet, the very
ame fact that OPCABG is typically reserved to higher risk patients
eans that this procedure may  often be considered in patients alsooncomitantly requiring mechanical circulatory support.
Mechanical circulatory support for patients undergoing OPCABG
ay  be provided by different means, but of course approaches
equiring substantially invasiveness appear counterintuitive in
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combination with the logic of reduced invasiveness inherent in the
choice of OPCABG. Accordingly, use of the Impella device in this spe-
ciﬁc setting could be particularly appealing.4,5 This device provides
substantial circulatory support up to 5.0 L/min while requiring only
the vascular insertion of a 21 French sheath. Despite its remark-
able hemodynamic performance and suitability for short as well
as mid-term usage, there has been so far no extensive experience
with use of the Impella device in patients undergoing OPCABG.
Given our favorable experience to date with the Impella device for
percutaneous coronary intervention and the fact that the device
ends with a soft-tipped section, and two anedoctal reports from
the literature,4,5 we hypothesized that it could be used safely and
effectively even for OPCABG. The case hereby reported supports
this hypothesis and warrants further exploration of the role and
larger series of Impella use in the setting of OPCABG.
Despite the favorable outcome of this case, complications
might have ensued and could occur with similar off-label use
of the Impella device, including device malfunction, device dam-
age, high purge pressure, valve dysfunction, device thrombosis,
coronary, cerebral, visceral or peripheral embolization, ventricular
perforation, bleeding, and vascular complications spanning from
dissection to thrombosis or bleeding.3 In addition, we did not
bypass the obtuse marginal branch or the posterior descending
artery in this case, but we believe this could have still been feasible
and safe using Impella. Accordingly, caution should be exercised
when envisioning the use of this type of mechanical circulatory
support, as well as a high index of suspicion to timely recognize
and address potentially life-threatening complications.
4. Conclusion
Use of the Impella Recover LP 5.0 device for patients undergo-
ing OPCABG is feasible and safe, and appears a promising strategy
to improve short- and long-term outcomes of patients undergoing
surgical coronary revascularization.
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